Biogen Inc. (BIIB) has been in the spotlight for various developments and occurrences. The biotech giant recently saw its shares being purchased by O Shaughnessy Asset Management LLC, while conversely, Epoch Investment Partners Inc. sold some of their shares. Despite
Alzheimer's drug Leqembi taking off, some cost reductions have underscored
profit estimates precisely. Unfortunately, the EU medicines regulator disapproved the Eisai-Biogen Alzheimer’s drug. Biogen and Ionis have decided to
discontinue development of an investigational ALS drug.
Revenue and profit declines have been witnessed as a result of Aduhelm costs and declining sales of multiple sclerosis. Class action lawsuits are ongoing against
Biogen, however, new data shows promise for potential treatments in early Alzheimer's. The company plans to
acquire HI-Bio to broaden their rare disease pipeline. Finally, the company’s first-quarter profit topped estimates owing to the improving uptake of its Alzheimer's drug.
Biogen BIIB News Analytics from Tue, 26 Sep 2023 07:00:00 GMT to Sun, 28 Jul 2024 20:48:00 GMT -
Rating -3
- Innovation -1
- Information 5
- Rumor 4
